A long-term health economics study of intraduodenal levodopa (Duodopa) in routine care for patients with advanced idiopathic Parkinson's disease with severe motor fluctuations and hyper-/dyskinesia.

Trial Profile

A long-term health economics study of intraduodenal levodopa (Duodopa) in routine care for patients with advanced idiopathic Parkinson's disease with severe motor fluctuations and hyper-/dyskinesia.

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Aug 2016

At a glance

  • Drugs Levodopa/carbidopa (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms DAPHNE
  • Sponsors Abbott Laboratories; Solvay Pharmaceuticals
  • Most Recent Events

    • 27 Jul 2011 Additional lead trial investigator (Sabine Neumann) identified as reported by ClinicalTrials.gov.
    • 27 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Jul 2011 Planned end date changed from 1 Sep 2010 to 1 Apr 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top